Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 9/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16699451 | 0.99 | MBOAT4 (0.51) | MBOAT4HRH3SLC6A4HTR4HTT | |
| SCHEMBL18166102 | 0.95 | MBOAT4 (0.48) | MBOAT4HRH3SLC6A4HTR4 | |
| SCHEMBL19971788 | 0.95 | MBOAT4 (0.48) | MBOAT4HRH3SLC6A4HTR4 | |
| SCHEMBL20009388 | 0.85 | MBOAT4 (0.38) | MBOAT4HRH3SLC6A4 | |
| SCHEMBL16699267 | 0.83 | MBOAT4 (0.39) | MBOAT4HRH3SLC6A4HTR4 | |
| SCHEMBL19979146 | 0.82 | MBOAT4 (0.59) | MBOAT4HRH3HTR4 | |
| SCHEMBL18166146 | 0.80 | MBOAT4 (0.46) | MBOAT4HRH3SLC6A4HTR4 | |
| SCHEMBL16699213 | 0.77 | MBOAT4 (0.69) | MBOAT4 | |
| SCHEMBL18166114 | 0.75 | MBOAT4 (0.66) | MBOAT4 | |
| SCHEMBL16728368 | 0.74 | MBOAT4 (0.77) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107454898-B | Ghrelin O-acyltransferase inhibitors | 伊莱利利公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| EP-3068775-B1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3068775-B1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-3068775-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | Eli Lilly and Company (US) | 2016-09-21 | — | — | EP | disclosed |
| CN-105636948-A | Substituted piperidinyl-ethyl-pyrimidines as gregorine O-acyltransferase inhibitors | LILLY CO ELI | 2016-06-01 | — | — | CN | disclosed |
| WO-2015073281-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073281-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885HRH3 4291/4885SLC6A4 1039/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885HRH3 4291/4885SLC6A4 1039/4885 |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | MBOAT4, DGAT1, MOGAT2 | MBOAT4 1/4885HRH3 4278/4885SLC6A4 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.